# OnCo record nct06254599 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06254599/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06254599", "NCT06254599" ;
  schema:name "A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC"@en ;
  schema:description "A phase 3 trial in lung cancer, run by Shouyao Holdings (Beijing) Co. LTD, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06254599/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06254599> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/alk-positive-nsclc/> .